Anne Noonan, MD
Hematology & Oncology · Columbus, OHNPI 1477887479
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $16,408 of the $25,257 with a category attached, or 65.0%. 11 manufacturers reported payments, led by AstraZeneca at 45.3% of the total.
Across 38 payments — averaging $664.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$11K
- Exelixis Inc.$4K
- Jazz Pharmaceuticals Inc.$3K
- Taiho Oncology, Inc.$2K
- Astrazeneca UK Limited$2K
- Eisai Inc.$2K
- plus $551 from 5 others
Across 122 payments — averaging $12,008 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$922K
- Merck$281K
- Ipsen Bioscience Inc.$98K
- Bristol Myers Squibb$47K
- Astrazeneca UK Limited$39K
- Coherus Oncology, Inc.$37K
- plus $41K from 3 others
What the payments were for
- Consulting fees$16,40865%
- Speaking & faculty fees$6,59626%
- Travel & lodging$6282%
- Food & beverage$1,5736%
- Education$510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 18 | $11,432 |
| Exelixis Inc. | 6 | $4,166 |
| Jazz Pharmaceuticals Inc. | 1 | $3,296 |
| Taiho Oncology, Inc. | 2 | $2,114 |
| Astrazeneca UK Limited | 1 | $2,055 |
| Eisai Inc. | 2 | $1,643 |
| Merck | 3 | $166 |
| Array Biopharma Inc | 1 | $139 |
| Pfizer | 1 | $105 |
| Janssen Scientific Affairs, LLC | 1 | $104 |
| Genentech USA, Inc. | 2 | $38 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,257 in reported general payments places this provider in the 80th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 22 | $33,944 |
| Prochlorperazine Maleate | 31 | $385 |
| Dexamethasone | 23 | $230 |
| Olanzapine | 18 | $178 |
| Oxycodone Hcl | 14 | $145 |
| Levothyroxine Sodium | 25 | $72 |
| Furosemide | 15 | $60 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Columbus
- Taral PatelColumbus$888K
- Tarek ChidiacColumbus$765K
- Sameh MikhailColumbus$135K
- Erin BertinoColumbus$73K
- Mark KnappColumbus$67K
- Kathleen KerriganColumbus$47K
- Hillard LazarusCleveland$2M
- Kasra KaramlouSandusky$1.8M
- David WaterhouseCincinnati$1.3M
- Saulius GirniusMontgomery$707K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.